MAP2K5 and posterior cortical atrophy: In biochemical terms the MEK5/ERK5 pathway is uniquely specific in that MEK5 appears to function entirely through activation of ERK5, suggesting that this pathway could be an attractive target for anticancer therapy in PCa.